Top

Osteoporosis International

Published in:

01-10-2012 | Original Article

A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke

Authors: J.-H. Kang, J. J. Keller, H.-C. Lin

Published in: Osteoporosis International | Issue 10/2012

Abstract

Summary

This study aimed to explore the effect of bisphosphonate treatment on stroke using a large population cohort study. We found that the patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (hazard ratio (HR) = 0.79; 95% confidence interval (CI) = 0.66–0.99; p = 0.005) during a 2-year follow-up period.

Introduction

Animal models have suggested that bisphosphonates have a beneficial effect on the cardiovascular system. However, data on this topic in human subjects are still lacking. This study aimed to explore the protective effect of bisphosphonate treatment on stroke using a large population cohort study.

Methods

We identified 2,148 patients who received bisphosphonate therapy for osteoporotic fractures. We randomly extracted 6,444 subjects with vertebral or hip fractures as a comparison group matched with the study group on age, sex, and year of index date. Each patient was individually tracked for 2 years to identify those who suffered a stroke. Stratified Cox proportional hazards regressions were performed to assess the effect of bisphosphonate treatment on the risk of stroke.

Results

We found that 184 (8.6%) patients who received bisphosphonate therapy and 696 (10.8%) comparison patients suffered a stroke during the follow-up period. After adjusting for demographic variables and medical co-morbidities, stratified Cox proportional hazards regressions stratified by propensity score revealed that patients who received bisphosphonate therapy were less likely to suffer a stroke than comparison patients (HR = 0.79; 95% CI = 0.66–0.99). The adjusted HR for subarachnoid/intra-cerebral hemorrhage for patients who received bisphosphonate therapy was only 0.53 times (95% CI = 0.33–0.92) that of comparison patients, and the hazard of having an ischemic stroke during the 2-year follow-up period was 0.81 times that of comparison patients (95% CI = 0.65–0.96).

Conclusion

Patients who received bisphosphonate therapy were associated with a lower risk of stroke during a 2-year follow-up period.

Woolf AD, Akesson K (2003) Preventing fractures in elderly people. BMJ 327:89–95PubMedCrossRef

Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289PubMedCrossRef

Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture intervention trial research group. Lancet 348:1535–1541PubMedCrossRef

Rodan GA, Reszka AA (2002) Bisphosphonate mechanism of action. Curr Mol Med 2:571–577PubMedCrossRef

Weinstein RS, Roberson PK, Manolagas SC (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62PubMedCrossRef

Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653–661PubMedCrossRef

Anagnostis P, Karagiannis A, Kakafika AI, Tziomalos K, Athyros VG, Mikhailidis DP (2009) Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities? Osteoporos Int 20:197–207PubMedCrossRef

Baldini V, Mastropasqua M, Francucci CM, D’Erasmo E (2005) Cardiovascular disease and osteoporosis. J Endocrinol Invest 28:69–72PubMed

Burnett JR, Vasikaran SD (2002) Cardiovascular disease and osteoporosis: is there a link between lipids and bone? Ann Clin Biochem 39:203–210PubMedCrossRef

10.

Tanko LB, Bagger YZ, Christiansen C (2003) Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 73:15–20PubMedCrossRef

11.

Mussolino ME, Madans JH, Gillum RF (2003) Bone mineral density and mortality in women and men: the NHANES I epidemiologic follow-up study. Ann Epidemiol 13:692–697PubMedCrossRef

12.

Strandberg TE (2008) Alendronate, osteoporosis, and atherosclerosis. Arch Intern Med 168:2386–2387PubMedCrossRef

13.

Watts N (2002) Bisphosphonates, statins, osteoporosis, and atherosclerosis. South Med J 95:578–582PubMed

14.

Ylitalo R (2003) Bisphosphonates and atherosclerosis. Gen Pharmacol 35:287–296

15.

Fiore CE, Pennisi P, Pulvirenti I, Francucci CM (2009) Bisphosphonates and atherosclerosis. J Endocrinol Invest 32:38–43PubMed

16.

Wu L, Zhu L, Shi WH, Zhang J, Ma D, Yu B (2009) Zoledronate inhibits the proliferation, adhesion and migration of vascular smooth muscle cells. Eur J Pharmacol 602:124–131PubMedCrossRef

17.

Ylitalo R, Syvala H, Tuohimaa P, Ylitalo P (2002) Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate. Pharmacol Toxicol 90:139–143PubMedCrossRef

18.

Ylitalo R, Monkkonen J, Urtti A, Ylitalo P (1996) Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med 127:200–206PubMedCrossRef

19.

Zhu BQ, Sun YP, Sievers RE, Isenberg WM, Moorehead TJ, Parmley WW (1994) Effects of etidronate and lovastatin on the regression of atherosclerosis in cholesterol-fed rabbits. Cardiology 85:370–377PubMedCrossRef

20.

Karam R, Camm J, McClung M (2007) Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357:712–713PubMed

21.

Delibasi T, Emral R, Erdogan MF, Kamel N (2007) Effects of alendronate sodium therapy on carotid intima media thickness in postmenopausal women with osteoporosis. Adv Ther 24:319–325PubMedCrossRef

22.

Celiloglu M, Aydin Y, Balci P, Kolamaz T (2009) The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis. Menopause 16:689–693PubMedCrossRef

23.

Tintut Y, Demer LL (2001) Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol 12:555–560PubMedCrossRef

24.

van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CW, Papapoulos SE (2003) Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 33:805–811PubMedCrossRef

25.

Buhaescu I, Izzedine H (2007) Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem 40:575–584PubMedCrossRef

26.

Dunford JE, Rogers MJ, Ebetino FH, Phipps RJ, Coxon FP (2006) Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res 21:684–694PubMedCrossRef

27.

Fujita H, Utsumi T, Muranaka S, Ogino T, Yano H, Akiyama J, Yasuda T, Utsumi K (2005) Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B. Biochem Pharmacol 69:1773–1784PubMedCrossRef

28.

Abedin M, Tintut Y, Demer LL (2004) Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol 24:1161–1170PubMedCrossRef

29.

Dobnig H, Hofbauer LC, Viereck V, Obermayer-Pietsch B, Fahrleitner-Pammer A (2006) Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients. Osteoporos Int 17:693–703PubMedCrossRef

30.

Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM (2008) Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 168:826–831PubMedCrossRef

31.

Sorensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA (2008) Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ 336:813–816PubMedCrossRef

32.

John Camm A (2010) Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. Clin Ther 32:426–443PubMedCrossRef

33.

Sheu JJ, Kang JH, Lou HY, Lin HC (2010) Reflux esophagitis and the risk of stroke in young adults: a 1-year population-based follow-up study. Stroke 41:2033–2037PubMedCrossRef

34.

Lin HC, Xirasagar S, Chen CH, Hwang YT (2008) Physician’s case volume of intensive care unit pneumonia admissions and in-hospital mortality. Am J Respir Crit Care Med 177:989–994PubMedCrossRef

35.

Wang LH, Lin HC, Lin CC, Chen YH, Lin HC (2010) Increased risk of adverse pregnancy outcomes in women receiving zolpidem during pregnancy. Clin Pharmacol Ther 88:369–374PubMedCrossRef

36.

Lin HL, Chen YH, Lin HC, Lin HC (2009) No increase in adverse pregnancy outcomes for women receiving antiepileptic drugs. J Neurol 256:1742–1749PubMedCrossRef

Title: A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke
Authors: J.-H. Kang
J. J. Keller
H.-C. Lin
Publication date: 01-10-2012
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 10/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-012-1894-0

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

A population-based 2-year follow-up study on the relationship between bisphosphonates and the risk of stroke

Abstract

Summary

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Summary

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2012

Evaluation of bone microarchitecture by high-resolution peripheral quantitative computed tomography (HR-pQCT) in hemodialysis patients

Precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges

Growth from birth to adulthood and peak bone mass and density data from the New Delhi Birth Cohort

The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml

What is the importance of “halo” phenomenon around bone cement following vertebral augmentation for osteoporotic compression fracture?